66
Participants
Start Date
April 30, 2014
Primary Completion Date
December 31, 2016
Study Completion Date
December 31, 2016
Urelumab
Cetuximab
Memorial Sloan Kettering Cancer Center, New York
Upmc Cancer Center, Pittsburgh
Johns Hopkins University, Baltimore
University Of Chicago, Chicago
Stanford University, Stanford
Providence Oncology & Hematology Care Eastside, Portland
Dana Farber Cancer Institute, Boston
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY